Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 31 July 2026.
SEP has backed the London-based operational resilience software provider in a growth equity round led by Tim Ankers and Jack Senior.
"We built resilienceOS to solve the challenge of relying on fragmented security systems to protect people and operations. Security and resilience teams want to focus on what matters most and need software to act as a force multiplier. Customers, employees, and shareholders expect leaders to adopt technology that safeguards people and protects businesses."
The pre-seed financing was led by Lazaroo-Hood Group to support product development.
"Money Squirrel was created to solve my own problem – the hours it took to move the VAT portion from every invoice into a separate, savings account."
The investment package includes £100m of debt funding to support liquidity in the UK digital economy.
"Over 50,000 UK businesses went under last year due to late payments. We are on a mission to eradicate this and this strategic investment is a game-changer for Revving and the entire digital economy"
The Manchester medtech company raised backing from the GMC Life Sciences Fund and NPIF II to expand its team and fulfill commercial contracts.
"Following a period of intensive development, during which we priortised quality, our customers’ needs and patient outcomes, I am delighted to see Pill Connect move into commercial adoption. Our dispensers are now being used in clinical trials, ensuring that one of the most critical factors – the drug being taken – is now both measurable and can be acted upon during a clinical trial."
The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
